Prosecution Insights
Prosecution Insights
Tech Center 3600 • Art Units: 1600 1621 1624 1625 1626 3646
This examiner grants 63% of resolved cases
Daniel John Burkett is an examiner in Tech Center 3600 and Art Unit 1600. He has handled 99 resolved cases. His allowance rate is 62.6 percent. This 62.6 percent rate suggests the probability of success for applicants whose cases are assigned to his docket in Art Unit 1600.
The interview lift for this examiner is 33.2 percent. This 33.2 percent lift is a significant metric, suggesting that direct communication is a powerful tool for advancing prosecution. Practitioners should prioritize interviews to leverage this increase in the probability of success for the 99 resolved cases analyzed. The data indicates that oral advocacy is highly effective in this context.
The median days to allowance is 1219. This 1219 day figure represents the typical time from filing to grant for applications in his portfolio. The 1219 day median provides a benchmark for pendency that applicants can use to forecast their own prosecution timelines. Understanding these metrics helps in managing expectations for the patent acquisition process in Tech Center 3600.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18958703 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING WET AGE-RELATED MACULAR DEGENERATION | Non-Final OA | UIF (University Industry Foundation), Yonsei University |
| 18251101 | CRYSTALLINE FORM II OF MELANOCORTIN RECEPTOR AGONIST COMPOUND AND PREPARATION METHOD THEREFOR | Non-Final OA | LG CHEM, LTD. |
| 18017732 | METHOD FOR PREPARING DEUTERATED AROMATIC COMPOUND AND DEUTERATED REACTION COMPOSITION | Final Rejection | LG CHEM, LTD. |
| 18855254 | COMBINATION METABOLIC-EPIGENETIC TREATMENT FOR EARLY LUNG CANCER | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 18262429 | METHOD FOR THE CONTROL OR SUPPRESSION OF PHYTOPATHOGENIC BACTERIA | Non-Final OA | SYNGENTA CROP PROTECTION AG |
| 18586471 | METHODS AND COMPOSITIONS FOR TREATING THROMBOTIC DISEASE | Final Rejection | WASHINGTON UNIVERSITY |
| 18228422 | SELECTIVE BRD4-DEGRADER MOLECULES | Final Rejection | Regents of the University of Minnesota |
| 18653324 | PENTAMIDINE ANALOGS | Non-Final OA | THE GENERAL HOSPITAL CORPORATION |
| 17911022 | 3-(2-(Aminoethyl)-Indol-4-ol Derivatives, Methods of Preparation Thereof, and the Use as 5-HT2 Receptor Modulators | Non-Final OA | The Medical College of Wisconsin, Inc. |
| 18176877 | INHIBITION OF URACIL DNA GLYCOSYLASE IN THE OPEN CONFORMATION | Non-Final OA | CASE WESTERN RESERVE UNIVERSITY |
| 18546322 | RADIOLABELED COMPOSITIONS AND METHODS OF USE THEREOF | Non-Final OA | The Research Foundation for the State University of New York |
| 18691241 | MEDICAMENT FOR PREVENTING AND/OR TREATING DRY EYE | Final Rejection | Boehringer Ingelheim International GMBH |
| 18373906 | TREATMENT OF MENTAL DISORDERS | Final Rejection | GH Research Ireland Limited |
| 18844821 | HOLOSYMMETRIC BIPHENYL DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Non-Final OA | Abbisko Therapeutics Co., Ltd. |
| 18692470 | EGFR INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | Non-Final OA | SHANDONG NEW TIME PHARMACEUTICAL CO., LTD. |
| 17597166 | IRAK DEGRADERS AND USES THEREOF | Final Rejection | Kymera Therapeutics, Inc. |
| 18191231 | ANTI-ACNE SKIN CARE COMPOSITIONS | Non-Final OA | Edgewell Personal Care Brands, LLC |
| 17909979 | Composition for Use in the Prophylaxis and Treatment of Viral Infections of the Asfarviridae Family | Non-Final OA | NUTRITION SCIENCES N.V. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy